Journal of Drug Targeting最新文献_第5页

Role of liposomes in chemoimmunotherapy of breast cancer.

IF 4.3 4区医学

Journal of Drug Targeting Pub Date : 2025-03-03 DOI: 10.1080/1061186X.2025.2467139

Fatemeh Attarian, Ghazaleh Hatamian, Shamim Nosrati, Mahsa Akbari Oryani, Hossein Javid, Alireza Hashemzadeh, Mojtaba Tarin

{"title":"Role of liposomes in chemoimmunotherapy of breast cancer.","authors":"Fatemeh Attarian, Ghazaleh Hatamian, Shamim Nosrati, Mahsa Akbari Oryani, Hossein Javid, Alireza Hashemzadeh, Mojtaba Tarin","doi":"10.1080/1061186X.2025.2467139","DOIUrl":"10.1080/1061186X.2025.2467139","url":null,"abstract":"In the dynamic arena of cancer therapeutics, chemoimmunotherapy has shown tremendous promise, especially for aggressive forms of breast cancer like triple-negative breast cancer (TNBC). This review delves into the significant role of liposomes in enhancing the effectiveness of chemoimmunotherapy by leveraging breast cancer-specific mechanisms such as the induction of immunogenic cell death (ICD), reprogramming the tumour microenvironment (TME), and enabling sequential drug release. We examine innovative dual-targeting liposomes that capitalise on tumour heterogeneity, as well as pH-sensitive formulations that offer improved control over drug delivery. Unlike prior analyses, this review directly links advancements in preclinical research-such as PAMAM dendrimer-based nanoplatforms and RGD-decorated liposomes-to clinical trial results, highlighting their potential to revolutionise TNBC treatment strategies. Additionally, we address ongoing challenges related to scalability, toxicity, and regulatory compliance, and propose future directions for personalised, immune-focused nanomedicine. This work not only synthesises the latest research but also offers a framework for translating liposomal chemoimmunotherapy from laboratory research to clinical practice.","PeriodicalId":15573,"journal":{"name":"Journal of Drug Targeting","volume":" ","pages":"1-29"},"PeriodicalIF":4.3,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143449167","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A review of recombinant HER3 affibodies with an effective diagnostic view of cancer cells. 综述重组 HER3 亲和体对癌细胞的有效诊断。

IF 4.3 4区医学

Journal of Drug Targeting Pub Date : 2025-03-01 Epub Date: 2024-11-21 DOI: 10.1080/1061186X.2024.2420202

Sahar Babaei Khorzoughi, Mehrnoosh Tavakoli, Mojtaba Mortazavi, Zahra Jafarnejad, Abdorrasoul Malekpour, Tara Kopaiee Malek, Farzane Kargar

{"title":"A review of recombinant HER3 affibodies with an effective diagnostic view of cancer cells.","authors":"Sahar Babaei Khorzoughi, Mehrnoosh Tavakoli, Mojtaba Mortazavi, Zahra Jafarnejad, Abdorrasoul Malekpour, Tara Kopaiee Malek, Farzane Kargar","doi":"10.1080/1061186X.2024.2420202","DOIUrl":"10.1080/1061186X.2024.2420202","url":null,"abstract":"Breast cancer is one of the leading causes of cancer-related deaths among women globally. Factors like increased expression of HER family members contribute to its development, with elevated HER3 levels-especially in conjunction with tyrosine kinase receptors like HER2-playing a critical role in activating cancer pathways essential for cell survival and proliferation. Detecting high HER3 levels is vital for effective treatment. Affibody proteins, a class that includes antibodies, are used to identify elevated HER3 expression due to their high binding affinity. These innovative non-immune probes show promise in therapy, diagnostics, and biotechnology because of their exceptional specificity and affinity for target proteins. The design of recombinant affibodies enhances HER3 detection accuracy and supports the development of targeted therapies. Advanced engineering techniques optimize these affibodies for stability and binding efficacy, making them suitable for clinical applications. Additionally, their versatility allows integration with imaging technologies for real-time monitoring of HER3 expression and therapeutic responses. This comprehensive approach could lead to more personalized treatment options for patients with HER3-positive breast cancers, improving patient management and outcomes. This study presents recombinant affibodies designed to bind HER3 for cancer cell identification and introduces novel methods for producing various affibody molecules.","PeriodicalId":15573,"journal":{"name":"Journal of Drug Targeting","volume":" ","pages":"316-327"},"PeriodicalIF":4.3,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142558003","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Evaluation of anti-diabetic effects of glimepiride/metformin cocrystal. 评估格列美脲/二甲双胍共晶体的抗糖尿病作用。

IF 4.3 4区医学

Journal of Drug Targeting Pub Date : 2025-03-01 Epub Date: 2024-11-22 DOI: 10.1080/1061186X.2024.2424901

Xiaoli Li, Duanfang Zhou, Mingpu Liu, Hongfang Zeng, Xiaoping Yu, Yi Song, Qichen He, Xu Liu, Huan Zhang, Zhengze Shen, Zeng Zhu, Mingyan Gu, Xiangnan Hu, Weiying Zhou

{"title":"Evaluation of anti-diabetic effects of glimepiride/metformin cocrystal.","authors":"Xiaoli Li, Duanfang Zhou, Mingpu Liu, Hongfang Zeng, Xiaoping Yu, Yi Song, Qichen He, Xu Liu, Huan Zhang, Zhengze Shen, Zeng Zhu, Mingyan Gu, Xiangnan Hu, Weiying Zhou","doi":"10.1080/1061186X.2024.2424901","DOIUrl":"10.1080/1061186X.2024.2424901","url":null,"abstract":"Emerging data suggest that cocrystal of two compounds may have a different pharmacological effect from two compounds alone or their physical combination. Glimepiride (Gli) and metformin (Met) are two types of anti-diabetic drugs. Previously, we generated the glimepiride/metformin cocrystal (GM). In this study, we evaluated the anti-diabetic effects of GM and explored the underlying mechanisms. Our result showed that GM reduced the blood glucose and HbA1c levels in db/db mice, and low doses of GM can achieve the hypoglycaemic effect as Gli or Met alone, and high dose of GM was better than Gli and Met alone in improving the pathological changes of liver. In vivo studies showed that GM activated AMPK and STAT3 signalling, downregulated TXNIP expression and upregulated MaFA expression. Moreover, GM promoted the secretion of insulin in pancreas of db/db mice and in high glucose-treated INS-1 and MIN-6 cells. Together, GM possesses slightly better anti-diabetic effects than Met or Gli alone in db/db mice, and the mechanism of GM protecting β-cell dysfunction induced by glucotoxicity may be associated with activation of the AMPK/TXNIP/MaFA pathway.","PeriodicalId":15573,"journal":{"name":"Journal of Drug Targeting","volume":" ","pages":"397-409"},"PeriodicalIF":4.3,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142558004","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Interactions and communications in the prostate tumour microenvironment: evolving towards effective cancer therapy. 前列腺肿瘤微环境中的相互作用和交流：向有效的癌症治疗发展。

IF 4.3 4区医学

Journal of Drug Targeting Pub Date : 2025-03-01 Epub Date: 2024-10-24 DOI: 10.1080/1061186X.2024.2418344

Qiang Dai, Yanling Peng, Peng He, Xiaojun Wu

{"title":"Interactions and communications in the prostate tumour microenvironment: evolving towards effective cancer therapy.","authors":"Qiang Dai, Yanling Peng, Peng He, Xiaojun Wu","doi":"10.1080/1061186X.2024.2418344","DOIUrl":"10.1080/1061186X.2024.2418344","url":null,"abstract":"Prostate cancer is one of the most common malignancies in men. The tumour microenvironment (TME) has a critical role in the initiation, progression, and metastasis of prostate cancer. TME contains various cell types, including cancer-associated fibroblasts (CAFs), endothelial cells, immune cells such as macrophages, lymphocytes B and T, natural killer (NK) cells, and other proteins such as extracellular matrix (ECM) components. The interactions and communications between these cells within the TME are crucial for the growth and response of various solid tumours, such as prostate cancer to different anticancer modalities. In this review article, we exemplify the various mechanisms by which the TME influences prostate cancer progression. The roles of different cells, cytokines, chemokines, and growth factors in modulating the immune response and prostate tumour growth will be discussed. The impact of these cells and factors and other ECM components on tumour cell invasion and metastasis will also be discussed. We explain how these interactions in TME can affect the response of prostate cancer to therapy. We also highlight the importance of understanding these interactions to develop novel therapeutic approaches for prostate cancer.","PeriodicalId":15573,"journal":{"name":"Journal of Drug Targeting","volume":" ","pages":"295-315"},"PeriodicalIF":4.3,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142501611","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

SIRT1: a potential therapeutic target for coronary heart disease combined with anxiety or depression. SIRT1：冠心病合并焦虑或抑郁的潜在治疗靶点

IF 4.3 4区医学

Journal of Drug Targeting Pub Date : 2025-03-01 Epub Date: 2024-12-23 DOI: 10.1080/1061186X.2024.2422882

Hubin Yu, Xinping Li, Bo Ning, Lanshuan Feng, Yaolong Ren, Shilin Li, Yalong Kang, Jing Ma, Mingjun Zhao

{"title":"SIRT1: a potential therapeutic target for coronary heart disease combined with anxiety or depression.","authors":"Hubin Yu, Xinping Li, Bo Ning, Lanshuan Feng, Yaolong Ren, Shilin Li, Yalong Kang, Jing Ma, Mingjun Zhao","doi":"10.1080/1061186X.2024.2422882","DOIUrl":"10.1080/1061186X.2024.2422882","url":null,"abstract":"Coronary heart disease (CHD) combined with anxiety or depression is increasingly receiving attention in the clinical field of cardiology, and exploring the comorbidity pathological mechanisms of cardiovascular disease combined with psychological disorders is a hot research topic for scholars in this field. Current research suggests that Silent Information Regulatory Factor 1 (SIRT1) may serve as a potential biomarker for the comorbidity mechanism and treatment of CHD with anxiety or depression. SIRT1 is considered a promising therapeutic target for CHD combined with anxiety or depression, with the ability to regulate inflammatory cytokine levels, alleviate oxidative stress damage, activate multiple signalling pathways, reduce platelet hyperresponsiveness, and exert neuroprotective and cardioprotective effects. In this comprehensive review, we deeply studied the structure, function, and mechanism of SIRT1, and discussed its protective effects in the cardiovascular and nervous system. The latest progress in the mechanism of SIRT1's role in CHD combined with anxiety or depression was emphasised, including its specific mechanisms in regulating inflammatory response, alleviating oxidative stress, and mediating various signalling pathways. In addition, this article also summarises the therapeutic potential of SIRT1 as a potential biomarker in patients with CHD combined with anxiety or depression.","PeriodicalId":15573,"journal":{"name":"Journal of Drug Targeting","volume":" ","pages":"328-340"},"PeriodicalIF":4.3,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142521969","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Integrating machine learning and multitargeted drug design to combat antimicrobial resistance: a systematic review. 整合机器学习和多靶点药物设计以对抗抗菌药耐药性：系统综述。

IF 4.3 4区医学

Journal of Drug Targeting Pub Date : 2025-03-01 Epub Date: 2024-11-26 DOI: 10.1080/1061186X.2024.2428984

Nagmi Bano, Salman Arafath Mohammed, Khalid Raza

{"title":"Integrating machine learning and multitargeted drug design to combat antimicrobial resistance: a systematic review.","authors":"Nagmi Bano, Salman Arafath Mohammed, Khalid Raza","doi":"10.1080/1061186X.2024.2428984","DOIUrl":"10.1080/1061186X.2024.2428984","url":null,"abstract":"Antimicrobial resistance (AMR) is a critical global health challenge, undermining the efficacy of antimicrobial drugs against microorganisms like bacteria, fungi and viruses. Multidrug resistance (MDR) arises when microorganisms become resistant to multiple antimicrobial agents. The World Health Organisation classifies AMR bacteria into priority list - I (critical), II (high) and III (medium), prompting action from nearly 170 countries. Six priority bacterial strains account for over 70% of AMR-related fatalities, contributing to more than 1.3 million direct deaths annually and linked to over 5 million deaths globally. Enterobacteriaceae, including Escherichia coli, Salmonella enterica and Klebsiella pneumoniae, significantly contribute to AMR fatalities. This systematic literature review explores how machine learning (ML) and multitargeted drug design (MTDD) can combat AMR in Enterobacteriaceae. We followed PRISMA guidelines and comprehensively analysed current prospects and limitations by mining PubMed and Scopus literature databases. Innovative strategies integrating AI algorithms with advanced computational techniques allow for the analysis of vast datasets, identification of novel drug targets, prediction of resistance mechanisms, and optimisation of drug molecules to overcome resistance. Leveraging ML and MTDD is crucial for both advancing our fight against AMR in Enterobacteriaceae, and developing combination therapies that target multiple bacterial survival pathways, reducing the risk of resistance development.","PeriodicalId":15573,"journal":{"name":"Journal of Drug Targeting","volume":" ","pages":"384-396"},"PeriodicalIF":4.3,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142621808","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Overcoming antibiotic resistance: the potential and pitfalls of drug repurposing. 克服抗生素耐药性：药物再利用的潜力与陷阱。

IF 4.3 4区医学

Journal of Drug Targeting Pub Date : 2025-03-01 Epub Date: 2024-11-12 DOI: 10.1080/1061186X.2024.2424895

Mohammad Abavisani, Alireza Khoshrou, Souzan Eshaghian, Sercan Karav, Amirhossein Sahebkar

{"title":"Overcoming antibiotic resistance: the potential and pitfalls of drug repurposing.","authors":"Mohammad Abavisani, Alireza Khoshrou, Souzan Eshaghian, Sercan Karav, Amirhossein Sahebkar","doi":"10.1080/1061186X.2024.2424895","DOIUrl":"10.1080/1061186X.2024.2424895","url":null,"abstract":"Since its emergence shortly after the discovery of penicillin, antibiotic resistance has escalated dramatically, posing a significant health threat and economic burden. Drug repositioning, or drug repurposing, involves identifying new therapeutic applications for existing drugs, utilising their established safety profiles and pharmacological data to swiftly provide effective treatments against resistant pathogens. Several drugs, including otilonium bromide, penfluridol, eltrombopag, ibuprofen, and ceritinib, have demonstrated potent antibacterial activity against multidrug-resistant (MDR) bacteria. These drugs can disrupt biofilms, damage bacterial membranes, and inhibit bacterial growth. The combination of repurposed drugs with conventional antibiotics can reduce the required dosage of individual drugs, mitigate side effects, and delay the development of resistance, making it a promising strategy against MDR bacteria such as Staphylococcus aureus, Klebsiella pneumoniae, Pseudomonas aeruginosa, and Escherichia coli. Despite its promise, drug repurposing faces challenges such as potential off-target effects, toxicity, and regulatory and intellectual property issues, necessitating rigorous evaluations and strategic solutions. This article aims to explore the potential of drug repurposing as a strategy to combat antibiotic resistance, examining its benefits, challenges, and future prospects. We address the legal, economic, and practical challenges associated with repurposing existing drugs, highlight successful examples, and propose solutions to enhance the efficacy and viability of this approach in combating MDR bacterial infections.","PeriodicalId":15573,"journal":{"name":"Journal of Drug Targeting","volume":" ","pages":"341-367"},"PeriodicalIF":4.3,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142558005","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

siRNA targeting PARP-1 alleviates diabetic peripheral neuropathy in a streptozotocin-induced rat model. 靶向 PARP-1 的 siRNA 可缓解链脲佐菌素诱导的大鼠模型中的糖尿病周围神经病变

IF 4.3 4区医学

Journal of Drug Targeting Pub Date : 2025-03-01 Epub Date: 2024-12-16 DOI: 10.1080/1061186X.2024.2431316

Moqbel Ali Moqbel Redhwan, Hariprasad M G, Suman Samaddar, Duaa Bafail, Sumaia Abdulbari Ahmed Ali Hard, Sourav Guha, Apurwa Dhavale

{"title":"siRNA targeting PARP-1 alleviates diabetic peripheral neuropathy in a streptozotocin-induced rat model.","authors":"Moqbel Ali Moqbel Redhwan, Hariprasad M G, Suman Samaddar, Duaa Bafail, Sumaia Abdulbari Ahmed Ali Hard, Sourav Guha, Apurwa Dhavale","doi":"10.1080/1061186X.2024.2431316","DOIUrl":"10.1080/1061186X.2024.2431316","url":null,"abstract":"Diabetic peripheral neuropathy (DPN) is a debilitating complication of diabetes mellitus, affecting nearly 50% of diabetic patients and leading to chronic pain, numbness and progressive sensory and motor function loss. This study investigates the potential of siRNA-mediated silencing of poly(ADP-ribose) polymerase 1 (PARP1) to alleviate DPN in a rat model. PARP1 overactivation, driven by hyperglycaemia-induced oxidative stress, exacerbates neuronal damage in DPN. Using chitosan nanoparticles (ChNPs) to deliver PARP1-targeting siRNA intrathecally in diabetic rats induced with streptozotocin (STZ) 55 mg/kg intraperitoneally, we conducted behavioural and physiological assessments, including Sciatic Functional Index (SFI), motor nerve conduction velocity (MNCV), grip strength and pain sensitivity tests, alongside qRT-PCR analyses, to evaluate therapeutic outcomes. Our findings indicate statistically significant improvements, with siRNA ChNPs-mediated PARP1 silencing alleviating neuropathic symptoms in DPN rats (p < .001 for SFI and MNCV improvements). Biochemical analyses revealed reductions in oxidative stress markers, such as MDA, and increased antioxidant levels, including GSH, CAT and SOD (p < .001). Pro-inflammatory cytokines and apoptotic markers, including NF-κB, IL6, IL1β, TNFa, TGF-β, CAS3, CAS9, BAK and BAX, also showed significant reductions (p < .01), confirming the neuroprotective effects of PARP1 inhibition. These results highlight the potential of siRNA-based therapies targeting PARP1 as a promising therapeutic approach for DPN, paving the way for future research with clinical applications.","PeriodicalId":15573,"journal":{"name":"Journal of Drug Targeting","volume":" ","pages":"424-435"},"PeriodicalIF":4.3,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142675065","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Drug screening approaches for small-molecule compounds in cancer-targeted therapy. 癌症靶向治疗中的小分子化合物药物筛选方法。

IF 4.3 4区医学

Journal of Drug Targeting Pub Date : 2025-03-01 Epub Date: 2024-11-22 DOI: 10.1080/1061186X.2024.2427185

Yelin Zhao, Chenyu Yuan, Yuchen Shi, Xiaohong Liu, Liaoxin Luo, Li Zhang, Milica Pešić, Hongjuan Yao, Liang Li

引用次数: 0

Reversal potentials of Tween 20 in ABC transporter-mediated multidrug-resistant cancer and treatment-resistant depression through interacting with both drug-binding and ATP-binding areas on MDR proteins. 吐温 20 通过与 MDR 蛋白上的药物结合区和 ATP 结合区相互作用，逆转 ABC 转运体介导的多药耐药性癌症和耐药性抑郁症的潜能。

IF 4.3 4区医学

Journal of Drug Targeting Pub Date : 2025-03-01 Epub Date: 2024-11-18 DOI: 10.1080/1061186X.2024.2429006

Yu-Cheng Ho, Wen-Chin Chiu, Jing-Yi Chen, Yu-Hsin Huang, Yu-Ning Teng

{"title":"Reversal potentials of Tween 20 in ABC transporter-mediated multidrug-resistant cancer and treatment-resistant depression through interacting with both drug-binding and ATP-binding areas on MDR proteins.","authors":"Yu-Cheng Ho, Wen-Chin Chiu, Jing-Yi Chen, Yu-Hsin Huang, Yu-Ning Teng","doi":"10.1080/1061186X.2024.2429006","DOIUrl":"10.1080/1061186X.2024.2429006","url":null,"abstract":"Drug efflux transporters, especially those belonging to the ATP-binding cassette (ABC) transporter superfamily, play a crucial role in various drug resistance issues, including multidrug resistance (MDR) in cancer and treatment-resistant depression (TRD) in individuals with major depressive disorder. Key transporters in this context include P-glycoprotein (P-gp), multidrug resistance protein 1 (MRP1), and breast cancer resistance protein (BCRP). This study aimed to investigate the modulatory effects of polyoxyethylene (20) sorbitan monolaurate (Tween 20) on these efflux transporters in vitro and to evaluate its potential for overcoming drug resistance in two models: an in vitro cancer MDR model and an in vivo TRD model. The findings indicated that 0.001% Tween 20 significantly inhibited the efflux actions of all three transporters. Additionally, 0.005% Tween 20 effectively reversed resistance to paclitaxel, vincristine, doxorubicin, and mitoxantrone in various cancer MDR cell lines. In the in vivo depression-like behaviour model, 0.01% Tween 20 markedly enhanced the antidepressant and anxiolytic effects of fluoxetine. Given its strong inhibitory effects on P-gp, MRP1, and BCRP, along with its capacity to reverse drug resistance both in vitro and in vivo, Tween 20 is a compelling candidate for tackling transporter-mediated drug resistance.","PeriodicalId":15573,"journal":{"name":"Journal of Drug Targeting","volume":" ","pages":"410-423"},"PeriodicalIF":4.3,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142621810","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0